Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.47 |
| ▸ | PDE6D | O43924 | 1/20 | 0.45 |
| ▸ | PDE6A | P16499 | 1/20 | 0.45 |
| ▸ | PDE6G | P18545 | 1/20 | 0.45 |
| ▸ | PDE6B | P35913 | 1/20 | 0.45 |
| ▸ | PDE6C | P51160 | 1/20 | 0.45 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830458 | 0.93 | PDE5A (0.53) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5831049 | 0.93 | PDE5A (0.47) | PDE5A | |
| SCHEMBL5259436 | 0.93 | PDE5A (0.54) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5260296 | 0.92 | PDE5A (0.55) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5261563 | 0.90 | PDE5A (0.52) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5830573 | 0.90 | PDE5A (0.46) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5830264 | 0.90 | PDE5A (0.51) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5261393 | 0.90 | PDE5A (0.47) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5257572 | 0.89 | PDE5A (0.48) | PDE5A | |
| SCHEMBL5829824 | 0.89 | PDE5A (0.49) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060824-B2 | Pyrrolotriazolopyrimidinone derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-06-13 | — | — | US | disclosed |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | VIDAL JUAN BERNAT (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6D 13/4885PDE6A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.